

Joshua J Gagne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/204945/joshua-j-gagne-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196 papers	3,505 citations	27 h-index	51 g-index
204 ext. papers	4,364 ext. citations	5.8 avg, IF	5.58 L-index

#	Paper	IF	Citations
196	Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.. <i>JAMA Network Open</i> , 2022 , 5, e220194	10.4	2
195	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1051-1060	27.4	1
194	Views from Academia, Industry, Regulatory Agencies, and the Legal System 2021 , 73-111		
193	Trends in Medicare Part D Inhaler Spending: 2012-2018. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 548-550	4.7	4
192	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. <i>American Heart Journal</i> , 2021 , 233, 109-121	4.9	9
191	Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 671-684	2.6	13
190	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. <i>Drug Safety</i> , 2021 , 44, 743-751	5.1	3
189	Association of California's Prescription Drug Coupon Ban With Generic Drug Use. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 2399-2402	27.4	1
188	Estimating Rebates and Other Discounts Received by Medicare Part D. <i>JAMA Health Forum</i> , 2021 , 2, e210626	10.6	10
187	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. <i>Value in Health</i> , 2021 , 24, 804-811	3.3	2
186	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1011-1017	6.1	5
185	Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021 , 128, 248-255	7.3	1
184	Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1353-1360	6.1	0
183	Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS). <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 320-333	2.6	
182	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. <i>Drug Safety</i> , 2021 , 44, 327-335	5.1	2
181	A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. <i>American Journal of Epidemiology</i> , 2021 , 190, 1424-1433	3.8	2
180	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 1214-1223	8	11

179	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020 , 80, 1961-1972	12.1	13
178	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. <i>Scientific Reports</i> , 2020 , 10, 10070	4.9	2
177	Bias in case-crossover studies of medications due to persistent use: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1079-1085	2.6	3
176	Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS). <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 890-903	2.6	2
175	Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018. <i>Drug Safety</i> , 2020 , 43, 669-675	5.1	5
174	Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 993-1000	2.6	1
173	Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation. <i>American Journal of Epidemiology</i> , 2020 , 189, 1467-1477	3.8	0
172	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. <i>American Heart Journal</i> , 2020 , 228, 36-43	4.9	6
171	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. <i>Cardiovascular Diabetology</i> , 2020 , 19, 25	8.7	10
170	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1093-1100	2.6	
169	Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications. <i>Value in Health</i> , 2020 , 23, 434-440	3.3	1
168	Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019. <i>JAMA Internal Medicine</i> , 2020 , 180, 1006-1008	11.5	7
167	Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. <i>American Journal of Managed Care</i> , 2020 , 26, 340-347	2.1	0
166	Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example. <i>Value in Health</i> , 2020 , 23, 217-226	3.3	0
165	Response to "The Self-Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions". <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 323	6.1	1
164	Validation of a comorbidity index for use in obstetric patients: A nationwide cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020 , 99, 399-405	3.8	8
163	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1334-1342	6.1	1
162	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 87-89	27.4	3

161	Exact sequential analysis for multiple weighted binomial end points. <i>Statistics in Medicine</i> , 2020 , 39, 340-351	3.1	1
160	Differences in characteristics of Medicare patients treated by ophthalmologists and optometrists. <i>PLoS ONE</i> , 2020 , 15, e0227783	3.7	3
159	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. <i>Epidemiology</i> , 2020 , 31, 806-814	3.1	3
158	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. <i>Annals of Internal Medicine</i> , 2020 , 172, 463-473	8	32
157	Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. <i>JAMA Internal Medicine</i> , 2020 , 180, 1596-1605	11.5	22
156	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 757-769	2.6	5
155	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate Real World Evidence of Comparative Effectiveness and Safety. <i>Drug Safety</i> , 2019 , 42, 1297-1309	5.1	6
154	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 238-244	6.1	11
153	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 374-384	27.4	18
152	Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 313-315	6.1	1
151	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1513-1521	6.1	10
150	Evaluation of Use of Technologies to Facilitate Medical Chart Review. <i>Drug Safety</i> , 2019 , 42, 1071-1080	5.1	1
149	Errors in Exclusion of Data and Reported Trends of Prescriptions in Study of Opioid Prescriptions Dispensed to Children and Adolescents. <i>JAMA Pediatrics</i> , 2019 , 173, 697	8.3	0
148	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2019 , 155, 1142-1152	5.1	32
147	Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 874-883	6.1	6
146	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching-A plasmode simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 879-886	2.6	2
145	The Devil is in the details: Reports on reproducibility in pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 671-679	2.6	2
144	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. <i>PLoS Medicine</i> , 2019 , 16, e1002763	11.6	26

143	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. <i>Drug Safety</i> , 2019 , 42, 85-93	5.1	3
142	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1156-1163	6.1	8
141	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , 2019 , 42, 1355-1363	5.1	1
140	Association of Opioid Overdose With Opioid Prescriptions to Family Members. <i>JAMA Internal Medicine</i> , 2019 , 179, 1186-1192	11.5	41
139	Days Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting - United States, 2014. <i>Morbidity and Mortality Weekly Report</i> , 2019 , 68, 140-143	31.7	12
138	Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 665-670	2.6	8
137	Methods for Studying the Health Effects of Drug-Drug Interactions 2019 , 1030-1045		
136	Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models 2019 , 617-638		5
135	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 113-121	1.9	11
134	Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1037-1042	6.7	6
133	Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017. <i>JAMA Pediatrics</i> , 2019 , 173, 98-99	8.3	14
132	A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. <i>Journal of General Internal Medicine</i> , 2019 , 34, 420-428	4	5
131	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. <i>Patient</i> , 2019 , 12, 235-246	3.7	3
130	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 707-712	2.6	7
129	Trends and Patterns of Corticosteroid Use During Coronary Artery Bypass Grafting Surgery in the United States. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 226-236	2.6	
128	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. <i>Cancer</i> , 2018 , 124, 2205-2211	6.4	4
127	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 383-390	2.6	1
126	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 1008-1015	6.1	3

125	Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. <i>Diabetes Care</i> , 2018 , 41, 713-722	14.6	20
124	Use of olmesartan and enteropathy outcomes: a multi-database study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 792-800	6.1	14
123	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 57-66	2.1	1
122	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 263-271	2.6	14
121	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. <i>BMJ, The</i> , 2018 , 361, k1180	5.9	18
120	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 567-569	2.6	6
119	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. <i>European Journal of Epidemiology</i> , 2018 , 33, 545-555	12.1	15
118	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. <i>American Journal of Epidemiology</i> , 2018 , 187, 1799-1807	3.8	25
117	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 731-739	2.6	5
116	Can Patient Navigators Improve Adherence to Disease-Modifying Antirheumatic Drugs? Quantitative Findings From a Six-Month Single-Arm Pilot Intervention. <i>Arthritis Care and Research</i> , 2018 , 70, 1400-1405	4.7	5
115	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2018 , 178, 1182-1189	11.5	39
114	Opioid Overdose After Surgical Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 502-504	27.4	26
113	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. <i>PLoS ONE</i> , 2018 , 13, e0200886	3.7	5
112	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004684	5.8	3
111	Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. <i>American Journal of Epidemiology</i> , 2018 , 187, 2439-2448	3.8	7
110	Patterns of opioid initiation at first visits for pain in United States primary care settings. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 495-503	2.6	17
109	Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 30-37	2.6	10
108	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1093-1099	6.1	10

107	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004632	5.8	17
106	Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. <i>Epidemiology</i> , 2018 , 29, 895-903	3.1	17
105	Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10. <i>Medical Care</i> , 2018 , 56, 812	3.1	10
104	Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1073-1082	2.1	1
103	A National Population-based Study of Adults With Coronary Artery Disease and Coarctation of the Aorta. <i>American Journal of Cardiology</i> , 2018 , 122, 2120-2124	3	8
102	Impact of a Metoprolol Extended Release Shortage on Post-Myocardial Infarction ßBlocker Utilization, Adherence, and Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004096	5.8	1
101	Using Previous Medication Adherence to Predict Future Adherence. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 1146-1155	1.9	15
100	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1361-1370	2.6	7
99	Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 1061-1068.e1	4.5	20
98	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. <i>Health Affairs</i> , 2018 , 37, 125-133	7	26
97	Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies-An application to the known association between angiotensin-converting enzyme inhibitors and angioedema. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 829-838	2.6	5
96	Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs. <i>Drug Safety</i> , 2018 , 41, 1313-1323	5.1	10
95	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 872-877	2.6	2
94	Generating Evidence of Clinical Outcomes of Drug-Drug Interactions. <i>Drug Safety</i> , 2017 , 40, 101-103	5.1	10
93	Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. <i>Journal of Comparative Effectiveness Research</i> , 2017 , 6, 25-32	2.1	10
92	New-user designs with conditional propensity scores: a unified complement to the traditional active comparator new-user approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 469-471	2.6	2
91	Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. <i>Drugs</i> , 2017 , 77, 427-433	12.1	5
90	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 694-701	2.6	4

89	Strength of evidence for labeled dosing recommendations in renal impairment. <i>Clinical Trials</i> , 2017 , 14, 219-221	2.2	1
88	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. <i>Drug Safety</i> , 2017 , 40, 923-932	5.1	10
87	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 200-209	1.7	15
86	The Potential Return on Public Investment in Detecting Adverse Drug Effects. <i>Medical Care</i> , 2017 , 55, 545-551	3.1	1
85	Evidence of potential bias in a comparison of β -blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. <i>BMJ Open</i> , 2017 , 7, e012997	3	5
84	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017 , 20, 1009-1022	3.3	47
83	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1507-1512	2.6	13
82	Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 914-916	6.1	3
81	Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. <i>BioResearch Open Access</i> , 2017 , 6, 159-168	2.4	4
80	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1018-1032	2.6	78
79	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. <i>Medical Care</i> , 2017 , 55, 1046-1051	3.1	30
78	Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. <i>Epidemiology</i> , 2017 , 28, 838-846	3.1	27
77	The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. <i>American Journal of Epidemiology</i> , 2017 , 185, 842-852	3.8	13
76	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. <i>Drug Safety</i> , 2017 , 40, 91-100	5.1	
75	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. <i>International Journal of Cardiology</i> , 2017 , 228, 761-770	3.2	17
74	Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 294-300	2.6	29
73	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. <i>American Journal of Cardiology</i> , 2017 , 119, 651-657	3	17
72	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. <i>European Journal of Cancer</i> , 2017 , 70, 22-33	7.5	20

71	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. <i>Drug Safety</i> , 2017 , 40, 105-108	5.1	2
70	Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network. <i>Current Epidemiology Reports</i> , 2017 , 4, 298-306	2.9	14
69	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , 2017 , 167, 845-854	8	33
68	Measuring drug exposure: concordance between defined daily dose and daysSupply depended on drug class. <i>Journal of Clinical Epidemiology</i> , 2016 , 69, 107-13	5.7	28
67	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. <i>Current Epidemiology Reports</i> , 2016 , 3, 277-284	2.9	8
66	Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis. <i>BMJ Open</i> , 2016 , 6, e010958	3	1
65	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. <i>American Journal of Epidemiology</i> , 2016 , 183, 949-57	3.8	13
64	Time for integrating clinical, lifestyle and molecular data to predict drug responses - AuthorsReply. <i>EBioMedicine</i> , 2016 , 7, 11	8.8	1
63	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. <i>Emerging Themes in Epidemiology</i> , 2016 , 13, 5	3.9	12
62	Variations in PatientsRPerceptions and Use of Generic Drugs: Results of a National Survey. <i>Journal of General Internal Medicine</i> , 2016 , 31, 609-14	4	40
61	PhysiciansRTrust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. <i>PLoS ONE</i> , 2016 , 11, e0163339	3.7	7
60	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1023-32	2.6	6
59	Balancing benefits and harms: privacy protection policies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 969-71	2.6	1
58	Developing alerting thresholds for prospective drug safety monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 755-62	2.6	
57	Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 798-814	2.6	7
56	Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 944-52	2.6	5
55	Effect of Generic Competition on Atorvastatin Prescribing and PatientsROut-of-Pocket Spending. <i>JAMA Internal Medicine</i> , 2016 , 176, 1317-23	11.5	22
54	Identification of Associations Between Prescribed Medications and Cancer: A Nationwide Screening Study. <i>EBioMedicine</i> , 2016 , 7, 73-9	8.8	17

53	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. <i>Journal of Clinical Epidemiology</i> , 2016 , 76, 200-8	5.7	16
52	Comparison of Calipers for Matching on the Disease Risk Score. <i>American Journal of Epidemiology</i> , 2016 , 183, 937-48	3.8	5
51	Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. <i>JAMA Internal Medicine</i> , 2016 , 176, 845-7	11.5	37
50	Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. <i>Diabetes Research and Clinical Practice</i> , 2016 , 115, 60-7	7.4	4
49	Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. <i>Neurology</i> , 2016 , 87, 1796-1801	6.5	26
48	Prescription Trends-Brand-Name Drugs vs Generic-Reply. <i>JAMA Internal Medicine</i> , 2016 , 176, 1574-1575	11.5	
47	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. <i>American Heart Journal</i> , 2016 , 180, 90-7	4.9	16
46	Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. <i>Drug Safety</i> , 2015 , 38, 849-53	5.1	6
45	Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. <i>Drugs</i> , 2015 , 75, 633-50	12.1	8
44	Comparative effectiveness of generic versus brand-name antiepileptic medications. <i>Epilepsy and Behavior</i> , 2015 , 52, 14-8	3.2	34
43	Thiazolidinediones and Parkinson Disease: A Cohort Study. <i>American Journal of Epidemiology</i> , 2015 , 182, 936-44	3.8	23
42	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , 2015 , 38, 1075-82	5.1	7
41	A unified framework for classification of methods for benefit-risk assessment. <i>Value in Health</i> , 2015 , 18, 250-9	3.3	15
40	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. <i>Value in Health</i> , 2015 , 18, 1063-9	3.3	3
39	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <i>Value in Health</i> , 2015 , 18, 1057-62	3.3	3
38	Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. <i>Drug Safety</i> , 2014 , 37, 151-61	5.1	13
37	"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. <i>American Journal of Epidemiology</i> , 2014 , 180, 636-44	3.8	14
36	Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. <i>Annals of Internal Medicine</i> , 2014 , 161, 400-7	8	107

35	Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 1160-7	2.6	11
34	Restrictive reimbursement policies: bias implications for claims-based drug safety studies. <i>Drug Safety</i> , 2014 , 37, 771-6	5.1	5
33	Ensuring patient privacy in data sharing for postapproval research. <i>New England Journal of Medicine</i> , 2014 , 371, 1644-9	59.2	8
32	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 619-27	2.6	20
31	Patients' preferences in anticoagulant therapy: discrete choice experiment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 912-9	5.8	22
30	Cigarette purchases at pharmacies by patients at high risk of smoking-related illness. <i>JAMA Internal Medicine</i> , 2014 , 174, 2031-2	11.5	4
29	Finding meaningful patterns in adverse drug event reports. <i>JAMA Internal Medicine</i> , 2014 , 174, 1934-5	11.5	6
28	Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. <i>Value in Health</i> , 2013 , 16, 1054-62	3.3	23
27	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013 , 146, 472-8	1.5	10
26	Statins and colorectal cancer risk: a longitudinal study. <i>Cancer Causes and Control</i> , 2013 , 24, 777-82	2.8	15
25	Development of a comorbidity index for use in obstetric patients. <i>Obstetrics and Gynecology</i> , 2013 , 122, 957-965	4.9	214
24	Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. <i>Epidemiology</i> , 2013 , 24, 375-8	3.1	22
23	Comment on Rempirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. <i>Statistics in Medicine</i> , 2013 , 32, 1073-4	2.3	1
22	On analyzing therapeutic ineffectiveness reports. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 207-8	3.6	1
21	Patterns and predictors of generic narrow therapeutic index drug use among older adults. <i>Journal of the American Geriatrics Society</i> , 2013 , 61, 1586-91	5.6	15
20	Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 542-50	2.6	55
19	Disease risk score as a confounder summary method: systematic review and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 122-9	2.6	33
18	Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. <i>Drug Safety</i> , 2012 , 35, 407-16	5.1	10

17	Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 480-6	5.8	116
16	An event-based approach for comparing the performance of methods for prospective medical product monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 631-9	2.6	10
15	Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 303-4; author reply 304	2.9	1
14	Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 590-6	6	28
13	A combined comorbidity score predicted mortality in elderly patients better than existing scores. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 749-59	5.7	548
12	Effects of adjusting for instrumental variables on bias and precision of effect estimates. <i>American Journal of Epidemiology</i> , 2011 , 174, 1213-22	3.8	163
11	How many "me-too" drugs is too many?. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 711-2	27.4	44
10	Availability of comparative efficacy data at the time of drug approval in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1786-9	27.4	41
9	Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. <i>Drugs</i> , 2010 , 70, 605-21	12.1	134
8	Confounder summary scores when comparing the effects of multiple drug exposures. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 2-9	2.6	42
7	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 259-68	2.6	20
6	Health advisories and patterns of patient monitoring among new users of antidepressant medications. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 590-4	1.7	
5	Assessing quality of care for migraineurs: a model health plan measurement set. <i>Population Health Management</i> , 2008 , 11, 203-8	1.8	3
4	Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 1125-32	2.8	82
3	Quality of care measures for migraine: a comprehensive review. <i>Disease Management: DM</i> , 2007 , 10, 138-46		10
2	Candidemia in the in-patient setting: treatment options and economics. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1643-50	4	22
1	Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. <i>Journal of Occupational and Environmental Medicine</i> , 2007 , 49, 252-7	2	12